HistoSonics' Histotripsy System Demonstrates 90% Local Tumor Control at 12 Months in #HOPE4LIVER Trials
MINNEAPOLIS--(BUSINESS WIRE)-- HistoSonics, the developer of the Edison Histotripsy System, announced today 12-month follow-up clinical data from its prospective #HOPE4LIVER trials, designed to evaluate the safety and efficacy of histotripsy for the non-invasive destruction of primary (hepatocellular cancer-HCC) and metastatic liver tumors.
'The one-year outcome data for the HOPE4LIVER trial are truly remarkable as the safety profile was maintained throughout the first year of follow-up ... and it became clear that the treatment effect was durable," Tim Ziemlewicz MD.
The Edison System, which received U.S. Food and Drug Administration (FDA) De Novo clearance in October 2023, uses focused ultrasound energy to mechanically destroy and liquefy targeted tissue and tumors without the invasiveness or toxicity of traditional procedures. These latest data reinforce histotripsy's potential to emerge as a new category of non-invasive therapy for patients suffering from liver tumors.
The #HOPE4LIVER trials enrolled 47 patients across 14 centers in the United States, United Kingdom and Europe, with tumors either originating in the liver or metastasizing to the liver, primarily from colorectal origins. The initial trial results published in 2024 were utilized by the FDA to support the De Novo marketing authorization in the US. In the trials, all patients treated with histotripsy had previously failed, were deemed ineligible for or were intolerant of standard therapies such as surgery, radiation, and ablation. As previously reported, the primary efficacy endpoint was successfully achieved in 95.5% of tumors treated as measured by the number of tumors where complete tumor coverage was achieved (42/44). Additionally, the co-primary safety endpoint of the trial was also achieved with only 3/44 (6.8%) of patients reporting a major complication. Adding to the strong safety profile, there was only a single Adverse Device Effect (ADE) reported beyond 30-days, and it was classified as non-serious, resolving on its own.
Nineteen patients had tumors originating from the liver (HCC) and 28 had metastatic tumors of the liver, with the most frequent originating from the colon or rectum (39.3%). A key finding in the 12-month follow-up analysis is a 90% local tumor control rate observed across all treated tumors regardless of tumor type or origin which compares favorably to current standard of care local regional therapies at one year.
The 12-month evaluation highlighted histotripsy's unique tendency to preserve critical collagen-rich structures, such as blood vessels and bile ducts, within the treated area due to its non-thermal, mechanical mechanism of action. An independent imaging core laboratory conducted post hoc radiographic assessments of all follow-up imaging to account for preserved vascular structures and ensured precise interpretation of treatment outcomes. Overall survival was analyzed using the Kaplan-Meier method, showing survival rates comparable to current systemic or combination therapies. Full interim 12-month results are published in the May 2025 issue of Annals of Surgery.
'It's very exciting to see these interim 12-month data,' said Clifford Cho, M.D., Chief Medical Officer at the University of Michigan Health-West and Co-Principal Investigator of the #HOPE4LIVER trials. 'As important as the initial report of #HOPE4LIVER was to the world of liver-directed therapy, it was absolutely necessary to follow those very early observations with longer-term data. We are not yet at a point where we can fully characterize the longitudinal effects of this brand-new technology, but these data confirm that the excellent local control and safety profile hinted at in our first #HOPE4LIVER paper are still there one year later. We will continue to do our due diligence with longer-term follow up, but I think these findings strongly support the rapid clinical adoption that we have seen for histotripsy.'
'The one-year outcome data for the #HOPE4LIVER trials are truly remarkable as the safety profile was maintained throughout the first year of follow-up and, as we gained understanding of the imaging findings post-histotripsy, it became clear that the treatment effect was durable,' said Tim Ziemlewicz, M.D., Professor of Radiology at the University of Wisconsin and Co-Principal Investigator of the #HOPE4LIVER trials. 'Local therapies have a long history of a steep learning curve before optimal outcomes can be achieved, while outcomes more equivalent to experienced users were achieved in this trial despite only a single investigator having prior experience treating patients with histotripsy. This speaks to the broad applicability of histotripsy and ensures that patients will have access to expert-level treatment from the earliest clinical adoption. This expands the number of patients we can successfully treat with local therapies, particularly for patients with tumors in critical locations, such as along central bile ducts, where histotripsy is rapidly becoming a leading treatment option.'
Histotripsy harnesses focused sound energy to create controlled acoustic cavitation, mechanically destroying and liquefying targeted liver tumors at the sub-cellular level. The HistoSonics platform uniquely enables physicians to plan, target, treat, and monitor tumor destruction with continuous real-time visualization and control—capabilities unmatched by any existing modality. Following FDA De Novo clearance in October 2023, the Edison Histotripsy System has been successfully adopted across leading U.S. academic centers, integrated health systems, and community hospitals eager to offer this breakthrough, non-invasive treatment to patients. Additional clinical trials are ongoing to evaluate the safety and efficacy of histotripsy in the non-invasive treatment of kidney tumors (#HOPE4KIDNEY Trial NCT05820087) and pancreatic tumors (GANNON Trial NCT06282809) in advance of planned regulatory submissions in both organs.
The Edison System is intended for the non-invasive mechanical destruction of liver tumors, including the partial or complete destruction of unresectable liver tumors via histotripsy. The FDA has not evaluated the Edison System for the treatment of any disease including, but not limited to, cancer or evaluated any specific cancer outcomes (such as local tumor progression, 5-year survival or overall survival). The System should only be used by physicians who have completed training performed by HistoSonics, and its use guided by the clinical judgment of an appropriately trained physician. Refer to the device Instructions for Use for a complete list of warnings, precautions, and a summary of clinical trial results, including reported adverse events.
About HistoSonics
HistoSonics is a privately held medical device company developing a non-invasive platform and proprietary sonic beam therapy utilizing the science of histotripsy, a novel mechanism of action that uses focused ultrasound to mechanically destroy and liquify unwanted tissue and tumors. The company is currently focused on commercializing their Edison System in the US and select global markets for liver treatment while expanding histotripsy applications into other organs like kidney, pancreas, and others. HistoSonics has offices in Ann Arbor, Michigan and Minneapolis, MN. For more information on the Edison Histotripsy System please visit: www.histosonics.com/. For patient-related information please visit: www.myhistotripsy.com/.
'The #HOPE4LIVER single-arm pivotal trial for histotripsy of primary and metastatic liver tumors: 1-year update of clinical outcomes' published in Annals of Surgery by Ziemlewicz, et.al. is licensed under CC BY-NC-ND.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Newsweek
an hour ago
- Newsweek
Dr Pepper Recall Issued After Sugar Mix Up in Thousands of Cans
A recall has been issued for thousands of cases of Dr Pepper Zero Sugar that were mislabeled and contained the full-sugar product, according to the U.S. Food and Drug Administration (FDA). The products were distributed to retailers in Florida, Georgia, and South Carolina. Newsweek contacted Keurig Dr Pepper, which owns the product in the United States, and PepsiCo, which bottled the beverages, for comment via email outside of regular working hours. Why It Matters This mislabeling poses potential health risks to consumers, particularly for individuals managing conditions like diabetes or those monitoring their sugar intake The FDA has issued a Class II risk classification for the recall, indicating that the consumption of the mislabeled products may cause temporary or medically reversible adverse health consequences. What To Know The FDA said the company-initiated recall affects 19,203 cases of Dr Pepper Zero Sugar 12-fluid ounce cans, sold in 12-pack and 24-pack cartons. The affected cans were produced at a Pepsi bottling facility in Jacksonville, Florida, which is licensed to manufacture Keurig Dr Pepper products, according to the FDA. The affected products have the product code XXXXRS05165, and a best-by date of February 16, 2026. The recall was initiated on May 23, 2025, and the FDA classified it as a Class II recall on June 5, 2025. A can of regular Dr Pepper contains 39 grams of sugar, while the Zero Sugar version has zero grams, but contains the artificial sweeteners aspartame and acesulfame potassium. There were 241 FDA food and beverage recalls in 2024, which was an increase of eight percent from the previous year, according to a report published by the nonprofit Public Interest Research Group. Undeclared allergens or ingredients was the single biggest cause for recalls that year. Last year, Dr Pepper tied with Pepsi to become the second most popular soda in the U.S. after Coca Cola, according to data from Beverage Digest. What Happens Next The FDA and Dr Pepper are working to ensure that all affected products are removed from store shelves promptly. Consumers in the affected states should remain vigilant and check their purchases to ensure they have not bought the mislabeled product.
Yahoo
9 hours ago
- Yahoo
FDA Reveals Which Kinds of Eggs May Be Contaminated with Salmonella
In a June news release, the U.S. Food and Drug Administration revealed that "brown cage-free and brown certified organic eggs" from the August Egg Company have "the potential" to be contaminated with salmonella. The outlet added that the eggs were "sold under multiple different brand names at restaurants and retailers" and should "no longer be available for sale." Those brands are Clover, First Street, Nuaid, O Organics, Marketside, Raleys, Simple Truth, Sun Harvest, and Sunnyside. According to People, over 1.7 million eggs have been recalled in nine states: California, Washington, Nevada, Arizona, Wyoming, New Mexico, Nebraska, Indiana, and Illinois. On June 6, 2025, the Centers for Disease Control and Prevention revealed they were investigating the "multi-state outbreak of salmonella infections." Mayo Clinic states that while some people with salmonella may have no symptoms, most experience a range of symptoms, like abdominal cramps, within 8 to 72 hours. "In some cases, diarrhea can cause severe dehydration and requires prompt medical attention. Life-threatening complications also may develop if the infection spreads beyond the intestines. The risk of getting salmonella infection is higher with travel to countries without clean drinking water and proper sewage disposal." At this time, 21 people have been hospitalized due to infection, according to the FDA. In a statement, the August Egg Company shared, "We believe it is appropriate out of an abundance of caution to conduct this voluntary recall, as consumers may still have these eggs in their homes. It is important to know that when our processing plant identified this concern, we immediately began diverting all eggs from the plant to an egg-breaking facility, which pasteurizes the eggs and kills any pathogens." The company concluded, "We are committed to addressing this matter fully and to implementing all necessary corrective actions to ensure this does not happen again."FDA Reveals Which Kinds of Eggs May Be Contaminated with Salmonella first appeared on Men's Journal on Jun 7, 2025
Yahoo
11 hours ago
- Yahoo
Salmonella outbreak causes egg recall; 79 people sick
(WTVO) — An egg producer based in California is recalling over a million eggs across nine states due to a salmonella outbreak, according to the (FDA). The specific type of eggs recalled was cage-free brown eggs manufactured by the August Egg Company. Those eggs were sold between February 3 and May 15. Select Walmart locations had the tainted eggs for sale, including stores in Illinois. They are also being recalled at Save Mart, FoodMaxx, Lucky, Smart & Final, Food 4 Less, Smart and Final, Safeway, Raleys and Ralphs. from the U.S. Centers for Disease Control and Prevention show that 79 people fell ill and 21 people went to the hospital in seven states. The specific container had a plant code number of P-6562 or CA5330 printed on the package. Salmonella infections can happen 12 to 72 hours after eating food that is contaminated. Symptoms of Diarrhea, fever and abdominal cramps can last from four to seven days, according to the . Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
